| Nov 14 |
Earnings Scheduled For November 14, 2024
|
| Nov 11 |
MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report
|
| Nov 7 |
MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024
|
| Oct 31 |
MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors
|
| Oct 9 |
MiNK Therapeutics Inc (INKT) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...
|
| Oct 8 |
MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
|
| Oct 4 |
MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024
|
| Jun 5 |
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
|
| May 22 |
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
|
